Failed, Interrupted, or Inconclusive Trials on Neuroprotective and Neuroregenerative Treatment Strategies in Multiple Sclerosis: Update 2015–2020Niklas Huntemann, Sven G. Meuth|Drugs|2021Cited by 35
Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumabSaskia Räuber, David Kremer, Karin von Wnuck Lipinski et al.|Journal of Neurology Neurosurgery & Psychiatry|2022Cited by 30
Eculizumab treatment alters the proteometabolome beyond the inhibition of complementChristopher Nelke, Tobias Ruck, Christina B. Schroeter et al.|JCI Insight|2023Cited by 10
Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple sclerosis receiving ocrelizumabSaskia Räuber, David Kremer, Alice Willison et al.|Frontiers in Immunology|2022Cited by 9